Xenetic Biosciences, Inc.
XBIOHealthcare|Biotechnology|US
$1.87
+0.01 (+0.31%)
Tangible Book / Share
$2.65
Cash / Share
$2.82
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03077698 An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer | Endometrial Cancer | P2 | Terminated | 25 | Open-label | Sodium Cridanimod, progestin therapy |